AMENDMENT NO. 3 TO MASTER CLINICAL TRIAL AGREEMENT BETWEEN NOVARTIS AND UT SYSTEM INSTITUTIONS

This Amendment No. 3 ("Amendment #3") to the Master Clinical Trial Agreement between Novartis Pharmaceuticals Corporation (Novartis) and certain institutions of The University of Texas System is made and entered into as of September 1, 2018 by and between Novartis and the following member institutions (each an "Institution" or collectively, "Institutions") of the University of Texas System ("UT System"): The University of Texas Health Science Center at San Antonio, The University of Texas Health Science Center at Houston, The University of Texas Health Science Center at Tyler, The University of Texas Medical Branch at Galveston, The University of Texas M.D. Anderson Cancer Center, The University of Texas Southwestern Medical Center, and The University of Texas at Austin.

RECITALS

A. Novartis and the following member Institutions of The University of Texas System entered into a Master Clinical Trial Agreement having an Effective Date of May 1, 2009 (the "Master Agreement"): The University of Texas Health Science Center at San Antonio, The University of Texas Health Science Center at Houston, The University of Texas Health Science Center at Tyler, The University of Texas Medical Branch at Galveston, The University of Texas M.D. Anderson Cancer Center, The University of Texas Southwestern Medical Center, and The University of Texas at Austin. Note, The University of Texas M. D. Anderson Cancer Center is no longer a party to the Master Agreement.

B. The parties have executed the following amendments to the Master Agreement:

1. Amendment #1 has an effective date on or around June 5, 2013 and amended
   - Section 9 A. Inventions and Patents;
   - Section 14A Clinical Trial Subject Injury; and
   - Added two Addenda: the first Addendum was entitled "Master Clinical Trial Agreement HCI/HCP Contract Addendum" and the second Addendum was entitled "Attachment A: Clinical Trial Request Form"

2. Amendment #2 has an effective date on or around April 10, 2014 and extended the term of the Master Agreement until April 30, 2019

C. Novartis and Institutions now wish to further amend the terms of the Master Agreement to include the amended terms as provided herein

NOW, THEREFORE, it is agreed that the Amendment #3 is amended as follows:

1. The Master Agreement, including its Preamble as provided in this section, is hereby amended to add "The University of Texas System" (for the benefit of
Clinical Trials Xpress) and "The University of Texas Rio Grande Valley" as parties to the Master Agreement with each being individually defined as "Institution" and collectively as "Institutions."

2. In the Preamble, the address for The University of Texas System is hereby amended to read: "210 West 7th Street, Austin, TX 78701."

3. The Preamble is hereby revised to add the following sentence to the end of the Preamble: "Additionally, see Attachment B for administrative contact information for each Institution."

4. Section 1 Scope of Work is hereby amended to add a new Subsection C, with the following text:

C. (1) Clinical Trials Xpress ("CTX") [www.clinicaltrialsxpress.org], a wholly-owned initiative of UT System, is the central coordinating office and team established to promote efficient and streamlined Clinical Trial study start-up processes and services for multi-institutional clinical trials. The CTX network operating model accelerates study implementation by negotiating a single, common clinical trial study budget; using pre-approved master clinical trial agreements and by adopting the UT System IRB Reciprocity model or central IRBs for regulatory oversight. Novartis, at its discretion, may engage the services of the CTX Central Coordinating Office (CCO) when the applicable Clinical Trial contemplated by this Master Agreement will be considered for participation by more than one Institution. Additionally, at Novartis' discretion, it may engage the services of CTX when only one Institution is participating in a Clinical Trial under this Master Agreement. As such, a separate Clinical Trial Request Form ("CTRF") between Novartis and CTX may be entered into for the services CTX will provide to Novartis (Attachment D: Schedule B is attached to Attachment A: Clinical Trial Request Form).

C. (2) Upon Novartis's approval and selection of at least one (1) CTX network site, Novartis shall pay CTX the costs outlined in the applicable Schedule B in exchange for CTX's performance of the activities listed on Attachment C as well as the activities listed immediately below:

(a) Within ninety (90) calendar days after CTX’s receipt: from Novartis of the Clinical Trial’s (i) Protocol (ii) informed consent form (ICF) template, (iii) CTRF template(s), (iv) Schedule A (budget) and (v) regulatory document package, CTX shall obtain and return to Novartis the following completed items for each site:

(i) a partially executed CTRF including an agreed upon Schedule A;

(ii) an original completed and signed FDA Form 1572 from each Principal Investigator;

Amend #3 to Master CTA
Master Term Extended to Aug 31, 2023
Novartis & UT System & UT System Health Institutions
OGC # 174385
(iii) a copy of the signed and dated final Protocol signature page from each Principal Investigator;

(iv) a current (within two years) signed and dated Curriculum Vitae for each Principal Investigator and all Sub-Investigators;

(v) an original completed, signed and dated Financial Disclosure Form for all individuals listed on each 1572;

(vi) proof of IRB submission and IRB review; and

(vii) a current IRB membership list (or FWA)

(b) Also, within in this same ninety (90) calendar day period, CTX shall, to the extent possible,

(i) obtain IRB approval of each site; and

(ii) ensure each Principal Investigator answers ICF questions and responds to IRB questions in a prompt manner;

(iii) Also, beginning within this same ninety (90) calendar day period and continuing through the completion of the Clinical Trial, CTX shall, to the extent possible, (i) ensure timely processing of all IRB submissions and regulatory document updates triggered by Protocol amendments, annual renewals and similar events (e.g., Investigational New Drug (IND) safety report) and

(iv) provide, when applicable, additional support and coordination of activities listed in Attachment C (CTX's Central Coordinating Office (CCO) Activities.

It is understood that such ninety (90) day period shall be tolled to the extent that CTX is unable to perform its work hereunder due to material delays caused by Novartis.

5. Section 2 - Agreement Term is hereby deleted and replaced with the following:

"The term of this Master Agreement is hereby extended to August 31, 2023."

6. A new Section 26 - Counterparts is hereby added after Section 25 and reads as follows:

26. Counterparts. This Master Agreement, and any subsequent amendment(s), may be executed in counterparts and the counterparts, together, shall constitute a single agreement. A "pdf" (portable document format) of this signed Master Agreement bearing a signature on behalf of a party shall be legal and binding on such party.

Amend #3 to Master CTA
Master Term Extended to Aug 31, 2023
Novartis & UT System & UT System Health Institutions
OGC # 174383
7. The signature blocks shall be amended to add two (2) additional signature blocks: one for "The University of Texas System for the benefit of Clinical Trials Xpress" and a second one for "The University of Texas Rio Grande Valley."

8. A new Attachment B entitled "Administrative Contact Person and Address for Each Institution" is hereby attached after Attachment A of the Master Agreement.

9. A new Attachment C entitled "CTX's Central Coordinating Office Roles and Responsibilities" is hereby attached after Attachment B.

10. A new Attachment D entitled "CTX Network Services" is hereby attached after Attachment C of the Master Agreement.

11. Except as expressly provided in this Amendment #3, all other terms, conditions and provisions of the Master Agreement shall continue in full force and effect as provided therein.

THIS AMENDMENT #3 IS EXECUTED by the authorized representatives of Novartis and the Institutions as of the dates indicated below.

SIGNED for and on behalf of Novartis Pharmaceuticals Corporation

[Signature]

Name: Melissa Shivas
Title: Head of Country Trial Operations
Date: 21-Nov-2018 | 6:46:57 PM EST

SIGNED for and on behalf of The University of Texas System for the benefit of Clinical Trials Xpress

[Signature]

Name: Raymond S. Greenberg, MD, PhD
Title: Executive Vice Chancellor for Health Affairs
Date: January 3, 2019

SIGNED for and on behalf of The University of Texas Health Science Center at Houston

[Signature]

Name: Chris G. Green, CPA
Title: Sr. Director, Office of Sponsored Programs

Amend #3 to Master CTA
Master Term Extended in Aug 31, 2023
Novartis & UT System & UT System Health Institutions
OGC # 174383
7. The signature blocks shall be amended to add two (2) additional signature blocks: one for “The University of Texas System for the benefit of Clinical Trials Xpress" and a second one for “The University of Texas Rio Grande Valley."

8. A new Attachment B entitled “Administrative Contact Person and Address for Each Institution" is hereby attached after Attachment A of the Master Agreement.

9. A new Attachment C entitled “CTX's Central Coordinating Office Roles and Responsibilities” is hereby attached after Attachment B.

10. A new Attachment D entitled “CTX Network Services” is hereby attached after Attachment C of the Master Agreement.

11. Except as expressly provided in this Amendment #3, all other terms, conditions and provisions of the Master Agreement shall continue in full force and effect as provided therein.

THIS AMENDMENT #3 IS EXECUTED by the authorized representatives of Novartis and the Institutions as of the dates indicated below.

SIGNED for and on behalf of
Novartis Pharmaceuticals Corporation

[Signature]

Name: Melissa Shivas
Title: Head of Country Trial Operations
Date: 21-Nov-2018 | 6:46:57 PM EST

SIGNED for and on behalf of
The University of Texas System for the benefit of Clinical Trials Xpress

[Signature]

Name:
Title:
Date:

SIGNED for and on behalf of
The University of Texas Health Science Center at Houston

[Signature]

Name:
Title:

Digitally signed by Kathleen Kreidler

Name: Kathleen M. Kreidler
Title: Associate Vice President
Science & Clinical Affairs
Date: 2018.12.21
14:03:14 -06'00'
Date:

SIGNED for and on behalf of
The University of Texas Health Science Center at Tyler

Signature
Name: Dena Walton
Title: Director of Sponsored Programs
Date: 12/5/2018 | 8:05:38 AM PST

SIGNED for and on behalf of
The University of Texas Southwestern Medical Center

Signature
Name:
Title:
Date:

SIGNED for and on behalf of
The University of Texas Rio Grande Valley

Signature
Name:
Title:
Date:

SIGNED for and on behalf of
The University of Texas Medical Branch at Galveston

Signature
Name:
Title:
Date:
Date:  

SIGNED for and on behalf of  
The University of Texas Health  
Science Center at Tyler  

Signature  
Name:  
Title:  
Date:  

Date:  

SIGNED for and on behalf of  
The University of Texas Medical  
Branch at Galveston  

Signature  
Name:  
Title:  
Date:  

Date:  

SIGNED for and on behalf of  
The University of Texas Southwestern Medical Center  

Signature  
Name:  
Title:  
Date:  

Date:  

SIGNED for and on behalf of  
The University of Texas at Austin  

Signature  
Name:  
Title:  
Date:  

Date:  

SIGNED for and on behalf of  
The University of Texas Rio Grande  
Valley  

Signature  
Name:  
Title:  
Date:  

Date:  

SIGNED for and on behalf of  
The University of Texas M.  
D. Anderson Cancer Center  

Signature  
Name:  
Title:  
Date:
<table>
<thead>
<tr>
<th>Date:</th>
<th>Date:</th>
</tr>
</thead>
</table>
| **SIGNED for and on behalf of**  
The University of Texas Health  
Science Center at Tyler | **SIGNED for and on behalf of**  
The University of Texas Medical  
Branch at Galveston |
| Signature | Signature |
| Name: | Name: |
| Title: | Title: |
| Date: | Date: |

<table>
<thead>
<tr>
<th>Date:</th>
<th>Date:</th>
</tr>
</thead>
</table>
| **SIGNED for and on behalf of**  
The University of Texas  
Southwestern Medical Center | **SIGNED for and on behalf of**  
The University of Texas at Austin |
| Signature | Signature |
| Name: | Name: |
| Title: | Title: |
| Date: | Date: |

<table>
<thead>
<tr>
<th>Date:</th>
<th>Date:</th>
</tr>
</thead>
</table>
| **SIGNED for and on behalf of**  
The University of Texas Rio Grande  
Valley | **SIGNED for and on behalf of**  
The University of Texas M.  
P. Anderson Cancer Center |
| Signature | Signature |
| Name: | Name: |
| Title: | Title: |
| Date: | Date: |

Amend B3 in Module CTA  
Module Term Extended to Aug 31, 2023  
Novartis & UT System & UT System Health Institutions  
OGC # 174385
Amend #3 to Master CTA
Master Term Extended to Aug 31, 2023
Novartis & UT System & UT System Health Institutions
OGC # 174385
## ATTACHMENT B
### ADMINISTRATIVE CONTACT PERSON AND ADDRESS FOR EACH INSTITUTION

<table>
<thead>
<tr>
<th>The University of Texas at Austin</th>
<th>The University of Texas Southwestern Medical Center</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mark Featherston</td>
<td>Megan G. Marks</td>
</tr>
<tr>
<td>Assistant Director, Contracts/Agreements</td>
<td>Assistant VP, Sponsored Programs Administrator</td>
</tr>
<tr>
<td>Office of Sponsored Projects</td>
<td>5323 Harry Hines Blvd.</td>
</tr>
<tr>
<td>P.O. Box 7726</td>
<td>Dallas, TX 75390-9105</td>
</tr>
<tr>
<td>Austin, Texas 78713-7726</td>
<td>Phone: 214-648-4139</td>
</tr>
<tr>
<td>Phone: 512-232-6087</td>
<td>Fax: 214-648-4474</td>
</tr>
<tr>
<td>Fax: 512-471-6584</td>
<td>Email: <a href="mailto:megan.marks@UTSouthwestern.edu">megan.marks@UTSouthwestern.edu</a></td>
</tr>
<tr>
<td>Tax ID: 74-600023</td>
<td></td>
</tr>
<tr>
<td>Email: <a href="mailto:mark.featherston@austin.utexas.edu">mark.featherston@austin.utexas.edu</a></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>The University of Texas Health Science Center at San Antonio</th>
<th>The University of Texas Health Science Center at Houston</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chris G. Green, CPA</td>
<td>Kristin L. Parks</td>
</tr>
<tr>
<td>Director, Office of Sponsored Programs</td>
<td>Director, Clinical Research Finance and Administration</td>
</tr>
<tr>
<td>7703 Floyd Curl Dr, Mail Code 7828</td>
<td>Office of Sponsored Projects Administration</td>
</tr>
<tr>
<td>San Antonio, TX 78225-3900</td>
<td>Fannin Street, UCT1002</td>
</tr>
<tr>
<td>Phone: 210-587-2340</td>
<td>Houston, TX 77030</td>
</tr>
<tr>
<td>Fax: 210-587-8107</td>
<td>Phone: 713-500-3063</td>
</tr>
<tr>
<td>Email: <a href="mailto:contracts@uthscsa.edu">contracts@uthscsa.edu</a></td>
<td>Fax: 713-383-3746</td>
</tr>
<tr>
<td></td>
<td>Email: <a href="mailto:Kristin.Parks@uth.tmc.edu">Kristin.Parks@uth.tmc.edu</a></td>
</tr>
<tr>
<td></td>
<td>Tax ID: 74-1781309</td>
</tr>
<tr>
<td></td>
<td><strong>Overnight address is:</strong></td>
</tr>
<tr>
<td></td>
<td>7000 Fannin Street, Suite UCT 1007-2</td>
</tr>
<tr>
<td></td>
<td>Houston, TX 77030</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>The University of Texas Health Science Center at Tyler</th>
<th>The University of Texas Medical Branch at Galveston</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dena Walton</td>
<td>Lori Simon</td>
</tr>
<tr>
<td>Director, Office of Pre-Award Services</td>
<td>Director, Office of Clinical Research</td>
</tr>
<tr>
<td>11937 U.S. Hwy. 271</td>
<td>6.170 Research Bldg. #6</td>
</tr>
<tr>
<td>Tyler, TX 75708-3154</td>
<td>Galveston, TX 77555</td>
</tr>
<tr>
<td>Phone: 903-877-7486</td>
<td>Phone: 409-772-1978</td>
</tr>
<tr>
<td>Fax: 903-877-7558</td>
<td>Fax: 409-772-1968</td>
</tr>
<tr>
<td>Email: <a href="mailto:dena.walton@uthct.edu">dena.walton@uthct.edu</a></td>
<td>Email: <a href="mailto:lasimon@utmmb.edu">lasimon@utmmb.edu</a></td>
</tr>
<tr>
<td></td>
<td>Email: <a href="mailto:clinical.research@utmmb.edu">clinical.research@utmmb.edu</a></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Clinical Trials Xpress</th>
<th>The University of Texas Rio Grande Valley</th>
</tr>
</thead>
<tbody>
<tr>
<td>Carla Kantara, PhD, M.B.A</td>
<td>Glorimar Colón, J.D.</td>
</tr>
<tr>
<td>Assoc. Vice President of Business Development</td>
<td>Office of the Senior VP for Research, Innovation, and</td>
</tr>
<tr>
<td>Collaborative Clinical Research Solutions, Inc.</td>
<td>Economic Development</td>
</tr>
<tr>
<td>Supports and Manages CTX for UT System</td>
<td>Research Liaison Officer</td>
</tr>
<tr>
<td>6341 Fannin Street, MSB 1.150</td>
<td>1201 West University Drive</td>
</tr>
<tr>
<td>Houston, TX 77030</td>
<td>Edinburg, TX 78539</td>
</tr>
<tr>
<td>O: (713) 500-7927</td>
<td>Phone: 956-665-3008</td>
</tr>
<tr>
<td>Email: <a href="mailto:carlakantara@ccrsconsultants.com">carlakantara@ccrsconsultants.com</a></td>
<td>Fax: 956-665-2940</td>
</tr>
<tr>
<td></td>
<td>Email: <a href="mailto:glorimar.colon@utrgv.edu">glorimar.colon@utrgv.edu</a></td>
</tr>
</tbody>
</table>
The University of Texas System
BethLynn Maxwell, Ph.D., J.D.
Chief Health Research Officer, Office of Health Affairs
Associate General Counsel, Office of General Counsel
210 West 7th Street
Austin, TX 78701
Phone: 512-499-4518
Fax: 512-499-4523
Email: bmiwell@utsystem.edu
Attachment C
CTX Central Coordinating Office Roles and Responsibilities

Network Engagement - CTX Initial Study Review & Feasibility Assessment

- Network Review of Protocol by Texas Regional CTSA Consortium (TRCC) Executive Committee (Clinical and Translational Science Award (CTSA) Lead PIs from CTSA awarded sites and Network Advisors) to decide whether to proceed with feasibility process at all participating UT sites ("sites").
- CTX to provide a single-source of Feasibility Assessment at all UT System Health Institutions.
- Once Master CDA put in place with Novartis, CTX to sign study confidentiality agreement on behalf of itself and all network sites.
- Identify and evaluate sites' interest
  - Identify physician investigators
  - Complete Novartis' Feasibility Questionnaire
  - Identify patient population at sites via Bioinformatics Analysis and with site physician input
  - Consolidate and summarize site responses
  - Review historical performance of sites in CTX databases to expedite feasibility process

Site Start-up Activities

- Within ninety (90) calendar days after CTX’s receipt from Novartis of the Clinical Trial’s (i) Protocol (ii) informed consent form (ICF) template, (iii) CTRF template(s), (iv) Schedule A (budget) and (v) regulatory document package, CTX shall Act as single point of contact to coordinate, review and approve CTRFs, trial-specific and site-specific content for all participating sites.
- Act as single point of contact for budget negotiations with all sites in order to expedite negotiations.
- To expedite quicker finalization of budget costs/terms, CTX will:
  - Initiate and coordinate the review of the trial-specific Schedule A (budget template) with each site.
  - Build consensus on budget with all sites and then present Novartis with a single common budget that has been approved by each site.
  - Once single common budget has been presented to Novartis, CTX will negotiate on all sites’ behalves with Novartis to resolve promptly any outstanding budget items.
  - Develop Medicare Coverage Analysis (MCA) for each Protocol.
• Coordinate, negotiate and finalize a standard informed consent form acceptable to each site for each Clinical Trial.
• Assist in the negotiation of pre-negotiated informed consent form language to be used for all Clinical Trials and acceptable to Novartis and all UT sites.
• Prepare and complete initial submission to Reviewing IRB.
• Identify and assist in the prompt resolution of any outstanding agreement and/or budget outliers between Novartis and sites.
• Oversee, coordinate, manage and expedite prompt final execution of CTRF between Novartis and sites.
• Support coordination of PSIV and SIV at all sites to encourage timely responses from participating UT sites and timely scheduling of such meetings.

Ongoing Network Operations, IRB & Regulatory Support

CTX shall continue to act as a single point of contact throughout the duration of the Clinical Trial to:

• Build Clinical Trial in the common CTMS (Velos e-Research or other mechanisms).
• Provide Clinical Trial performance metrics to support monthly operational calls/meetings with Novartis.
• Troubleshoot and resolve network issues relative to each Clinical Trial.
• At Novartis’ written request, create patient recruitment flyers & other marketing materials to support study. This task will be contingent on the availability of a predetermined allocated budget for marketing activities, agreed upon by Novartis and CTX.
• Work with Novartis’ Clinical Research Associate (CRA), bioinformaticians, navigators and others to develop patient study-specific recruitment plan and action plans as needed.
• Conduct monthly meetings with sites to assess progress of the Clinical Trial and to report such progress to Novartis.
• Conduct monthly meetings with Novartis to review current status of active Clinical Trials.
• CTX will act as the single point of contact to coordinate, oversee and manage all regulatory documents and IRB submissions on behalf of all sites for the life of the Clinical Trial, including those triggered by any protocol amendments, and all other submissions required by Novartis.
• Complete submission of amendments to Reviewing IRB as needed.
• Obtain Permission to Rely forms from each site and submit to the Reviewing IRB.
• Build and Maintain e-Regulatory Binder for all sites for the life of the Clinical Trial.
• Provide CTX e-Portal training to Clinical Trial-related Novartis and site study personnel, as needed.
- The e-portal allows for real time availability of information to sponsor clinical research associates (CRAs) and institutional personnel needing access to review regulatory information in format that mirrors the sponsor's regulatory binder to support local and remote auditing activities (study and site specific).
- The e-portal maintains current and historical documents for the life of the study. CTX historical documents (e.g. consents, protocols) are locked in a folder such that the site can view but cannot download the most current version of these documents.

- Manage CTX e-Portal user access codes and uploading of documents.
- Facilitate escalation and resolution of Clinical Trial issues and ensure adherence to Clinical Trial activation timelines.
## Attachment D
Schedule B for CTX CTRF

**Clinical TrialsXpress**

**CTX NETWORK SERVICES**

<table>
<thead>
<tr>
<th>SERVICE ACTIVITY</th>
<th>Estimated Cost (USD)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Network Engagement – CTX Initial Study Review &amp; Feasibility Assessment</td>
<td>($13,000 Per Study)</td>
</tr>
<tr>
<td><em>Initial contact through study acceptance by TRCC Executive Committee (TEC) and 1+ site(s) selected by Novartis.</em></td>
<td></td>
</tr>
<tr>
<td>Site Start-up Activities</td>
<td>($4,550/site for Year 1)</td>
</tr>
<tr>
<td><em>Study Start-up Activities initiated upon receipt of final protocol, Novartis budget, consent and other IRB materials.</em></td>
<td></td>
</tr>
<tr>
<td>Ongoing Network Operations, IRB &amp; Regulatory Support</td>
<td>($8,450 = $6,500 per site per year + Annual IRB Renewal Fee $1,950 per site per following year through study close-out)</td>
</tr>
<tr>
<td><em>Study initiation through close out.</em></td>
<td></td>
</tr>
<tr>
<td>IRB/Regulatory Fees</td>
<td>1st Amendment - no charge</td>
</tr>
<tr>
<td>Protocol Amendment fees</td>
<td>Subsequent Amendments $650 per site per amendment</td>
</tr>
</tbody>
</table>

Amend #3 to Master CTA
Master Term Extended to Aug 31, 2023
Novartis & UT System & UT System Health Institutions
OGC # 174385
Payment Schedule and Assumptions

- The Network Engagement Fee is non-refundable for work actually performed. If Novartis terminates the study or study sites' participation prior to study initiation, CTX will prorate the Network Engagement Fee to the extent that activities have not already been performed.

- Fees for ongoing network operations and regulatory support will be invoiced quarterly.

- The fees for the Site Start-up Activities include the initial IRB submission and up to 1 protocol amendment. Additional fees will be applied to subsequent amendments (minor and major) and annual IRB renewal submissions (years two through close-out).

- When adding additional CTX network sites to an existing (open) Clinical Trial, a fee of only $4,550 per site will be charged, there is not a second subsequent Network Engagement Fee.

- Payment is requested within thirty (30) days of invoice. For timely processing of your payment, please reference the CTX Invoice Number specified above on your ACH payment.

- UT System represents that the CTX fee structure reflects fair market value for the services provided and resources associated with those activities.

- CTX will notify Novartis of any changes to the Attachment D - Schedule B CTX CTRF fee structure prior to engaging CTX services for a specific trial.

*Payment requested within thirty (30) days of receipt. For timely processing of your payment, please reference the CTX Invoice number specified above on your ACH payment.*

<table>
<thead>
<tr>
<th>ACH Payment Instructions</th>
<th>Payment by Check</th>
</tr>
</thead>
<tbody>
<tr>
<td>BANK NAME</td>
<td>JP MORGAN CHASE</td>
</tr>
<tr>
<td>BANK ADDRESS</td>
<td>221 WEST 6TH ST.</td>
</tr>
<tr>
<td>AUSTIN, TX 78701</td>
<td></td>
</tr>
<tr>
<td>ACCOUNT TYPE</td>
<td>CHECKING</td>
</tr>
<tr>
<td>ROUTING NUMBER</td>
<td>110000614</td>
</tr>
<tr>
<td>ACCOUNT NUMBER</td>
<td>133318010</td>
</tr>
<tr>
<td>BANK CONTACT</td>
<td>KENNETH JAMES</td>
</tr>
<tr>
<td>713-236-3053</td>
<td></td>
</tr>
<tr>
<td>REFERENCE NO. UTS OHA CTX-</td>
<td></td>
</tr>
<tr>
<td>ATTENTION</td>
<td>ROBERT BUCKINGHAM</td>
</tr>
<tr>
<td>OFFICE OF HEALTH AFFAIRS</td>
<td></td>
</tr>
<tr>
<td>UNIVERSITY OF TEXAS SYSTEM</td>
<td></td>
</tr>
<tr>
<td>210 WEST 7TH ST.</td>
<td></td>
</tr>
<tr>
<td>15TH FLOOR</td>
<td></td>
</tr>
<tr>
<td>AUSTIN, TEXAS 78701</td>
<td></td>
</tr>
<tr>
<td>512-499-4226</td>
<td></td>
</tr>
<tr>
<td>REFERENCE NO. UTS OHA CTX-</td>
<td></td>
</tr>
</tbody>
</table>